DNTH
NASDAQDianthus Therapeutics Inc.
Price$81.33-1.71 (-2.06%)
01:30 PM07:45 PM
News · 26 weeks64+50%
2025-12-142026-06-07
Mix4190d
- Insider17(41%)
- SEC Filings11(27%)
- Other7(17%)
- Offering4(10%)
- Analyst2(5%)
Latest news
25 items- INSIDEREVP, Head of R&D Randhawa Simrat exercised 26,530 shares at a strike of $18.85 and sold $2,404,077 worth of shares (26,530 units at $90.62) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- PRDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 60,000 shares of the Compa
- PRDianthus Therapeutics to Participate in Two Investor ConferencesNEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026. Ryan Savitz, EVP, CFO and CBO of Dianthus Therapeutics, will participate in a fireside chat on Wednesday, June 3, 2026, at 12:45 p.m. ET and will host one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference. Marino Garcia, CEO of Dianthus Therapeutics, will participate in a fireside chat on Tuesday, June 9, 2026, at 2:40 p.m. ET and
- INSIDERSEC Form 4 filed by Director Lawton Alison Frances4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Romano Steven J.4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Mcgeorge Anne4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Read Simon4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Violin Jonathan4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Soteropoulos Paula4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- INSIDERSEC Form 4 filed by Director Kango Sujay4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECDianthus Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- PROorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic DiseasesCompany announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients ORJ-001, set to begin a Phase 2 clinical trial in IPF in 2026, is a novel approach to restore the function of alveolar epithelial type 2 (AEC2) cells that are central to the pathogenesis of pulmonary fibrosis HOUSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Oorja Bio, Inc., a clinical-stage biopharmaceutical company developing groundbreaking therapies for fibrotic and cardiopulmonary diseases, today announced the company's launch and $30 million in Series A financing from its founding investor, Westlake BioPartners. The
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dianthus Therapeutics Inc.SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Dianthus Therapeutics Inc.SCHEDULE 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)
- INSIDERDirector Soteropoulos Paula exercised 599 shares at a strike of $8.44 and sold $51,197 worth of shares (599 units at $85.47) as part of a pre-agreed trading plan (SEC Form 4)4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- PRLBL-047 Prioritized for Clinical Development in Sjögren's Disease, Systemic Lupus Erythematosus, and DermatomyositisNANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (("Dianthus", NASDAQ:DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China). Strategic Priority: Advancing Clinical Development of LBL-047 LBL-047 is a potential first- and best-in-disease bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/AP
- SECSEC Form 10-Q filed by Dianthus Therapeutics Inc.10-Q - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECDianthus Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- PRDianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial ResultsEarly GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A Claseprubart granted Orphan Drug Designation by FDA for Myasthenia Gravis Phase 3 registrational trial of claseprubart evaluating 300mg/2mL Q2W and 300mg/2mL Q4W in generalized Myasthenia Gravis (gMG) on track to initiate in mid-2026; top-line results anticipated in 2H'28 Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing; top-line results on track for Q4'26 Phase 1 healthy volunteer data for DNTH212 anticipated in 2H'26 Building a rheumatology franchise around DNTH212 with firs
- PRDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., May 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on May 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares of the Company'
- INSIDERSEC Form 4 filed by Savitz Ryan4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)
- SECSEC Form DEFA14A filed by Dianthus Therapeutics Inc.DEFA14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- SECSEC Form DEF 14A filed by Dianthus Therapeutics Inc.DEF 14A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)
- ANALYSTWolfe Research initiated coverage on Dianthus Therapeutics with a new price targetWolfe Research initiated coverage of Dianthus Therapeutics with a rating of Outperform and set a new price target of $98.00
- PRDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK and WALTHAM, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on April 1, 2026, to eight newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grants consist of non-qualified stock options to purchase an aggregate of 135,000 shares of the Co
DNTH FAQ
6 questionsWhere does DNTH stock trade?
Dianthus Therapeutics Inc. (DNTH) is listed on NASDAQ.What sector and industry is DNTH in?
Dianthus Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Dianthus Therapeutics Inc. go public?
Dianthus Therapeutics Inc. (DNTH) completed its IPO in 2018.What are analysts saying about DNTH?
Dianthus Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform on 2026-04-09. Recent price targets cluster around $4800.00.What companies are similar to DNTH?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare DNTH side-by-side with any of them on Quantisnow.How can I track DNTH on Quantisnow?
Quantisnow aggregates Dianthus Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DNTH to receive live email and push alerts on every new disclosure.